Athira Pharma, Inc. (ATHA)

0.4290 +0.0040 (+0.94%) At close: 04:00PM EDT

Athira Pharma, Inc.

18706 North Creek Parkway
Suite 104
Bothell, WA 98011
United States
425 620 8501
https://www.athira.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark J. Litton M.B.A., Ph.D.	President, CEO & Director	882.7k	N/A	1968
Mr. Robert Renninger	VP of Finance, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1984
Dr. Kevin Church Ph.D.	Chief Scientific Officer	123.67k	N/A	1985
Ms. Julie Rathbun	Head of Investor Relations	N/A	N/A	N/A
Mr. Mark F. Worthington J.D.	General Counsel & Corporate Secretary	503.83k	N/A	1966
Ms. Samantha Willing	Chief People Officer	N/A	N/A	N/A
Dr. Javier San Martin M.D.	Chief Medical Officer	N/A	N/A	1965

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Corporate governance

Athira Pharma, Inc.’s ISS governance QualityScore as of 1 October 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.